Incyte Corporation
INCY Healthcare Biotechnology
Incyte Corporation’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 21.2% from fiscal 2024. In the quarter to June 2026, revenue grew 37.7%, EPS grew 39.7%, free cash flow grew 1,829.5% and total debt fell 10.5%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for ten consecutive years.
Follow INCY
Incyte Corporation (INCY) Net income
Incyte Corporation's net income for fiscal 2025 was $1.3B, up 3,845.0% from $32.6M in fiscal 2024. Over the twelve months to 30 June 2026 it was $1.6B. Over the past ten years it has ranged from −$313.1M (fiscal 2017) to $1.3B (fiscal 2025) — the current reading is the highest in ten years. Incyte Corporation ranks 3rd of 630 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $1.3B | 3,844.96% |
| FY2024 | $32.6M | (94.54%) |
| FY2023 | $597.6M | 75.42% |
| FY2022 | $340.7M | (64.09%) |
| FY2021 | $948.6M | — |
| FY2020 | −$295.7M | — |
| FY2019 | $446.9M | 308.16% |
| FY2018 | $109.5M | — |
| FY2017 | −$313.1M | — |
| FY2016 | $104.2M | 1,495.80% |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | $585.6M | 93.06% |
| Mar 2026 | $303.3M | 1.35% |
| Dec 2025 | $299.3M | (29.44%) |
| Sep 2025 | $424.2M | 4.73% |
| 42 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| INCY Incyte Corporation | $1.6B |
| RPRX Royalty Pharma PLC compare | $1.3B |
| GMAB Genmab A/S Sponsored ADR compare | $906.0M |
| ASND Ascendis Pharma A/S compare | $865.9M |
| EXEL Exelixis, Inc. compare | $860.6M |
| ALNY Alnylam Pharmaceuticals, Inc. compare | $774.7M |
| ROIV Roivant Sciences Ltd. compare | −$414.6M |
| INSM Insmed, Inc. compare | −$875.3M |
| BNTX BioNTech SE Sponsored ADR compare | −$1.9B |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on INCY
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement